Advances in the treatment of Crohn's disease and ulcerative

$ 15.00

4.5
(597)
In stock
Description

When used in a treat-to-target approach, therapies for mucosal healing may favorably modify the natural history of inflammatory bowel disease (IBD), reducing the need for steroids and risk of hospitalization.

mojtaba shafiekhani on LinkedIn: Pharmacokinetic and Pharmacodynamic Considerations of Novel Antibiotic…

VMS BioMarketing on LinkedIn: UCB's Bimekizumab is Now Available

Satellite Symposia - DDW

NEPC20 AGENDA – Connecticut Pharmacists Association

specialized ibd, SAVE 16%

Dr. Edward V. Loftus, MD, Rochester, MN, Gastroenterologist

specialized ibd, SAVE 16%

Digestive Diseases News - Medical Professionals - Mayo Clinic

Are Biologics Right for You?

Son los productos biológicos los indicados para usted?

Digestive Diseases News - Medical Professionals - Mayo Clinic

NEPC20 AGENDA – Connecticut Pharmacists Association